PT - JOURNAL ARTICLE AU - Torres Zambrano, Gina M. AU - Rivero, Rene Antonio AU - Villegas Valverde, Carlos A. AU - Carmenate, Yendry Ventura TI - Features and outcomes of secondary sepsis and urinary tract infections in COVID-19 patients treated with stem cell nebulization AID - 10.1101/2020.12.05.20244483 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.05.20244483 4099 - http://medrxiv.org/content/early/2020/12/07/2020.12.05.20244483.short 4100 - http://medrxiv.org/content/early/2020/12/07/2020.12.05.20244483.full AB - Background COVID-19 is the defining global crisis of our time. Secondary complication such as urinary tract infections and sepsis, worsen the already established problem, creating a new challenge.Objective To characterize the features and outcomes in COVID-19 patients with sepsis and urinary tract infection.Methods An observational and analytical study was conducted within the framework of the SENTAD COVID clinical trial at the Abu Dhabi Stem Cells Center, were the patients received a nebulization therapy with the use of autologous stem cells (group A). Those patients were compared with a not stem cells treated control arm (group B), and both received the UAE COVID 19 standard management. An analysis of the culture samples, antimicrobial agents and the efficacy of the therapy on patient’s outcomes was done.Results A significant difference between the groups was found in the UTI incidence (p=*0.0206). Patients in group A showed a lower tendency to sepsis in comparison with group B (7% vs 21%), HR=0.35, (95% Confidence Interval: 0.13 – 0.91), p=0.0175. It was calculated a NNT=7.3. Candida albicans was the most frequently agent causing sepsis and UTI. The massive use of broad-spectrum antimicrobials was striking.Conclusions We found a protective factor of stem cells against secondary infection in COVID 19 cases, in terms of sepsis and UTI. The suggested immunomodulatory effect of stem cells offers a therapeutic strategy to manage the disease and avoid several complications. Antimicrobial agents can lead to increased opportunistic infections, so a rational approach to these treatments must be considered.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04473170Clinical Protocols https://clinicaltrials.gov/ct2/show/study/NCT04473170?term=stem+cell&cond=covid&cntry=AE&draw=2&rank=1. Funding StatementThis work was supported by ADSCC. This research had not received any other specific grant from any funding agency in the public, commercial or not-for-profit sectors. Award/Grant number is not applicable.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Emirates Institutional Review Board for COVID-19 Research (Ref. ID: DOH/CVDC/2020/1172).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExtra data is available by emailing dr.torresz@gmail.com.